Mepolizumab Reduced Corticosteroid Use in COPD Patients
Analysis of Phase 3 clinical trials shows mepolizumab cuts annual steroid exposure and high-dose treatment days for COPD patients.
Category: US Pharmaceuticals
US Pharmaceuticals
Latest
Mepolizumab Reduced Corticosteroid Use in COPD Patients
Analysis of Phase 3 clinical trials shows mepolizumab cuts annual steroid exposure and high-dose treatment days for COPD patients.
Read More
Federal Grant to Fund Inhaled Vaccines
A $20.7M federal grant will fund a 5-year inhaled vaccines initiative at the Icahn School of Medicine at Mount Sinai beginning with development of an avian influenza nasal spray prototype.
Read More
Prescription Drug Prices Continue to Surge
Initial prices for brand-name medications climbed steadily over two decades, with no immediate slowdown following the Inflation Reduction Act.1
Read More
FDA Grants Priority Review for Arikayce Inhaled Antibiotic for MAC
The FDA accepted Insmed’s supplemental new drug application with Priority Review for Arikayce to treat Mycobacterium avium complex (MAC) lung disease.
Read More
Cryospray Improved COPD Symptoms
Clinical trial results showed CSA Medical’s Metered CryoSpray procedure significantly eases chronic lung symptoms and lowers severe hospital events.
Read More
Gene Variant Reduced Benefit of Pediatric Asthma Drug
A study indicates pediatric asthma patients with a common gene variant may experience diminished response to mepolizumab during viral infections.
Read More
RSV Monoclonal Antibodies Highly Effective in Infants
Global analysis of more than 60,000 RSV viral sequences reveals that resistance to monoclonal antibodies remains rare.
Read More
FDA Launches Pilot Program to Speed Early Clinical Trials
The FDA’s Expedited Investigational New Drug (IND) Pilot pairs drug sponsors with research institutions to reduce startup delays for early human studies.
Read More
Cardiovascular, Sleep Improvements Should Guide Obesity Pharmacotherapies
A new scientific statement from the Endocrine Society emphasizes health outcomes such as sleep apnea and heart disease over weight loss alone.
Read More
Semaglutide Tied to Fewer Asthma, COPD Exacerbations
The diabetes and weight loss injection semaglutide was associated with fewer asthma attacks and COPD exacerbations, according to ERS 2026 research.
Read More
Merck Wants to Extend RSV Vaccine to Second Season
FDA will review Enflonsia’s ability to protect high-risk children under 2 years of age during their second RSV season.
Read More
Application Accepted for Inhaled Pulmonary Fibrosis Treatment
If cleared by federal regulators, nebulized Tyvaso (treprostinil) Inhalation Solution would become the first inhaled option designed to treat idiopathic pulmonary fibrosis (IPF).
Read More
FDA Approves Updated COVID-19 Vaccines for 2026-2027
Updated formulas from Pfizer, Moderna, and Novavax target the circulating XFG variant for older adults and high-risk populations.
Read More
Asthma Antiviral Nasal Spray Secures Funding for Clinical Trial
A clinical trial will evaluate a weekly dry powder nasal spray’s ability to boost natural defenses and prevent asthma infections.
Read More
CVS, Walgreens Now Offering Seasonal Flu Vaccines
CVS and Walgreens are expanding walk-in access, multi-vaccine scheduling, and respiratory illness testing ahead of peak viral activity.
Read More
Study to Evaluate Effectiveness of Brensocatib for Bronchiectasis
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
Read More
FDA Approves OTC 12-Hour Cold and Fever Medication
The FDA approved over-the-counter Mucinex 12hr Cold & Fever Multi-Symptom.
Read More
FDA Approves First mRNA Flu Vaccine
The FDA approved Moderna’s mFlusiva, the first seasonal influenza vaccine using mRNA technology to enter the US market.
Read More
FDA to Review RSV Drug Enflonsia for Children 2 and Younger
Merck is seeking expand approval for its RSV drug Enflonsia to include children under age two through their second year of risk.
Read More
Azithromycin vs Roflumilast for AECOPD
A UCLA Health study compared azithromycin and roflumilast in protecting against acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Read More
FDA Approves Orzeyful for Narcolepsy Type 1
Orzeyful is the first drug to target the underlying loss of orexin signaling to address the full range of narcolepsy type 1.
Read More
Remdesivir Tied to Better Long-Term Health for Kidney Transplant Recipients With COVID-19
In kidney transplant recipients, early antiviral treatment with remdesivir reduced the risk of organ rejection and heart complications by nearly half for up to one year after diagnosis.
Read More
Duchenne Muscular Dystrophy Cell Therapy Preserves Heart, Muscle Function
Results from the HOPE-3 trial found that an investigational cell therapy called deramiocel preserved heart and muscle function in boys and young men with Duchenne muscular dystrophy (DMD).
Read More
Experimental Monoclonal Antibody Improved ARDS Outcomes
A proof-of-concept study showed an experimental monoclonal antibody targeting ARDS inflammation increased ventilator-free days and reduced organ failure.
Read More